Protara Insider Trades Signal Confidence Ahead of ASCO Phase‑2 Reveal
Protara Therapeutics insider trades reveal executive confidence in TARA‑002’s market access, highlighting how upcoming Phase‑2 data could boost pricing strategy and competitive positioning in bladder‑cancer immunotherapy.
4 minutes to read